349 results match your criteria: "Centre d'Investigation Clinique (CIC)[Affiliation]"
J Neurol
December 2024
Service de Médecine Interne, Centre de Référence Des Maladies Héréditaires du Métabolisme, UMR INSERM 1253 « iBraiN », Université de Tours, CHU de Tours, Tours, France.
Background And Objective: Adult patients with early-treated phenylketonuria (AwET-PKU) may present some subtle neurocognitive deficits. The aim of the study was to investigate 1) neurocognitive functions in a large group of AwET-PKU 2) the influence of plasma phenylalanine (Phe).
Methods: Participants: 187 AwET-PKU (classic PKU [cPKU] 81%, mild PKU [mPKU] 14%, and mild persistent hyperphenylalaninemia [MPH] 5%).
Am J Clin Nutr
December 2024
Nantes Université, Centre Hospitalier Universitaire de Nantes INRAE, Nantes, France.
Background: Preeclampsia (PE) contributes to maternal and fetal mortality and morbidity. Supplementation with L-arginine, the precursor of nitric oxide, has not proven effective, possibly due to extensive arginine catabolism in the splanchnic bed. Citrulline is converted by the kidney to L-arginine.
View Article and Find Full Text PDFRev Neurol (Paris)
October 2023
Service de Neurologie, CHRU Cavale-Blanche, Brest, France; Université Brest, Inserm, EFS, UMR 1078, GGB, 29200 Brest, France. Electronic address:
ESMO Open
November 2024
Department of Medical Oncology, Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France; Residual Tumor and Response to Treatment, RT2Lab, INSERM, U932 Cancer & Immunity, Institut Curie, Université Paris Sciences Lettres, Paris, France; Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hôpitaux de Paris (AP-HP), Centre d'Investigation Clinique (CIC-1901), Pharmacology Department, Pitié-Salpêtrière Hospital, Paris, France. Electronic address:
The older population represents ∼50%-60% of the population of newly diagnosed patients with cancer. Due to physiological and pathological aging and the increased presence of comorbidities and frailty factors, this population is at higher risk of serious toxicity from anticancer drugs and, consequently, often under-treated. Despite the complexity of these treatments, a good knowledge of the pharmacology of anticancer drugs and potentially risky situations can limit the emergence of potentially lethal toxicities in this population.
View Article and Find Full Text PDFFront Physiol
September 2024
Laboratoire MOVE UR 20296 - UR, Faculté des Sciences du Sport-STAPS, Université de Poitiers, Poitiers, France.
Purpose: To investigate the effects of a repeated-sprint training in hypoxia induced by voluntary hypoventilation at low lung volume (RSH-VHL) including end-expiratory breath holding (EEBH) of maximal duration.
Methods: Over a 4-week period, twenty elite judo athletes (10 women and 10 men) were randomly split into two groups to perform 8 sessions of rowing repeated-sprint exercise either with RSH-VHL (each sprint with maximal EEBH) or with unrestricted breathing (RSN, 10-s sprints). Before (Pre-), 5 days after (Post-1) and 12 days after (Post-2) the last training session, participants completed a repeated-sprint ability (RSA) test on a rowing ergometer (8 × 25-s "all-out" repetitions interspersed with 25 s of passive recovery).
Pediatr Allergy Immunol
October 2024
Centre de Recherche Cardio-thoracique de Bordeaux, Univ. Bordeaux, INSERM U1045, Pessac, France.
Kidney Int
November 2024
Université Paris Cité, INSERM U970, Paris Institute for Transplantation and Organ Regeneration, Paris, France; Department of Kidney Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address:
Non-invasive biomarkers are promising tools for improving kidney allograft rejection monitoring, but their clinical adoption requires more evidence in specifically designed studies. To address this unmet need, we designed the EU-TRAIN study, a large prospective multicentric unselected cohort funded by the European Commission. Here, we included consecutive adult patients who received a kidney allograft in nine European transplant centers between November 2018 and June 2020.
View Article and Find Full Text PDFToxicon
October 2024
. Intensive Care Unit, Cayenne General Hospital, French Guiana; . Tropical Biome and Immunopathology CNRS UMR-9017, Inserm U 1019, Université de Guyane, French Guiana; . Laboratory of Medicinal and Environment Chemistry, Higher Institute of Biotechnology, University of Sfax, PB 261, Sfax, 3000, Tunisia.
Prenat Diagn
September 2024
FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.
J Thromb Haemost
November 2024
AP-HP, Groupe Hospitalier Universitaire AP-HP-Nord, Université Paris Cité, Research Clinic, Epidemiology, Biostatistic Department, Hôpital Bichat-Claude Bernard, DMU PRISME, Paris, France; AP-HP, INSERM, Hôpital Pitié Salpétrière, Centre de Pharmaco - Epidémiologie (Cephepi), Centre d'Investigation Clinique CIC-1901, Paris, France; Université Paris Sorbonne, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpétrière, Département de Santé Publique, Centre de Pharmaco-Epidémiologie (Cephepi), CIC-1901, Paris, France.
Background: Preoperative identification of patients with hemostasis abnormalities leading to an increased bleeding risk is based on routine hemostasis tests: prothrombin time (PT), activated partial thromboplastin time (APTT), and platelet count. Because of their low predictive performance, guidelines recommend replacing them with structured bleeding risk questionnaires, but none is validated in this population.
Objectives: To assess the diagnostic accuracy of 3 strategies, performed at the preanesthesia visit before scheduled interventions, and to identify patients with hemostasis abnormalities leading to an increased bleeding risk METHODS: A multicenter study was performed in 7 French academic hospitals, involving patients scheduled for surgical intervention, without antiplatelet/anticoagulant treatment.
Front Pharmacol
July 2024
Centre de Recherche Cardio-thoracique de Bordeaux, INSERM U1045, Bordeaux Imaging Center, University Bordeaux, Pessac, France.
Eur J Phys Rehabil Med
October 2024
INSERM - Centre d'Investigation Clinique (CIC 1432), Module Plurithématique, Plateforme d'Investigation Technologique (PIT), CHU Dijon-Bourgogne, Dijon, France -
Background: This randomized controlled trial examined the feasibility of adding eccentric exercise to a conventional cardiac rehabilitation program (CCRP) for coronary heart disease patients.
Methods: Ninety-three patients were randomly assigned to either the MIX group (eccentric ergometer + CCRP) or the CON group (concentric ergometer + CCRP) for 7 weeks. Training effectiveness was assessed based on "good responders" showing improved functional capacities, such as 6-minute walk test (6MWT) distance and maximal voluntary contraction of the plantar flexors (ankle MVC).
J Eur Acad Dermatol Venereol
July 2024
Département de Dermatologie, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France.
Background: Bullous pemphigoid (BP) affects older patients with numerous comorbidities. The impact of BP on patient autonomy remains poorly understood.
Objectives: To assess the frequency and factors associated with functional decline (FD) in BP.
Nicotine Tob Res
November 2024
Unité de Recherche Clinique Pierre Deniker, Centre Hospitalier Henri Laborit, Poitiers, France.
Introduction: Increased salience of drug-related cues over nondrug reinforcers can drive drug use and contribute to tobacco use disorder (TUD). An important scientific and clinical goal is to effectively measure this elevated drug-seeking behavior in TUD. However, most TUD assessments rely on self-reported cravings and cigarette consumption, not providing an objective measure of the impact of drug cues on biasing behavior toward drugs.
View Article and Find Full Text PDFFront Psychiatry
May 2024
Unité de Recherché Clinique Intersectorielle en Psychiatrie à vocation régionale du Centre Hospitalier Henri Laborit, Poitiers, France.
Background: The present study evaluated the therapeutic efficacy and tolerability of 10 transcranial direct current stimulation (tDCS) sessions in treatment-resistance obsessive-compulsive disorder (OCD) patients using a multisite double-blind sham-controlled design.
Methods: Eighty treatment-resistance outpatients suffering from obsessive-compulsive disorder were randomized to receive either active or sham transcranial direct current stimulation. The cathode was positioned over the supplementary motor area and the anode over the right supraorbital area.
Sci Rep
May 2024
INSERM U-1084, Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, Poitiers, France.
Impulsivity dimensions have been shown to be associated with smoking status and tobacco use disorder severity. However, it is important to determine the specific impulsivity traits associated with smoking relapse. This study aimed at investigating the associations between impulsivity traits and smoking cessation success among adult smokers at 12 months after a quit attempt.
View Article and Find Full Text PDFNeurol Clin Pract
August 2024
University of Minnesota Medical School (GR); Greg Marzolf Jr. Muscular Dystrophy Center (SAS, ALD, HRL, CCB, CAP, PBK); Department of Neurology (SAS, ALD, WGM, HRL, CCB, CAP, PBK), University of Minnesota Medical School; Institute on the Biology of Aging and Metabolism (PDR, LJN), University of Minnesota, Minneapolis; Clinical Genetics (AA, PG, SM), Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom; Department of Pediatric Neurology/Centre d'investigation Clinique (CIC) (VL), Strasbourg University Hospital, France; and Institute for Translational Neuroscience (PBK), University of Minnesota, Minneapolis.
Diabetologia
August 2024
Institut Necker Enfants Malades, Inserm U1151, CNRS UMR 8253, IMMEDIAB Laboratory, Paris, France.
JAMA Netw Open
April 2024
INSERM, U1111, CNRS, UMR 5308, CIRI-GIMAP, Université Claude Bernard Lyon 1, Université Jean Monnet, Immunology and Immunomonitoring Laboratory, iBiothera, CIC 1408, Saint-Étienne, France.
Importance: There is still considerable controversy in the literature regarding the capacity of intramuscular messenger RNA (mRNA) vaccination to induce a mucosal immune response.
Objective: To compare serum and salivary IgG and IgA levels among mRNA-vaccinated individuals with or without previous SARS-CoV-2 infection.
Design, Setting, And Participants: In this cohort study, SARS-CoV-2-naive participants and those with previous infection were consecutively included in the CoviCompare P and CoviCompare M mRNA vaccination trials and followed up to day 180 after vaccination with either the BNT162b2 (Pfizer-BioNTech) vaccine or the mRNA-1273 (Moderna) vaccine at the beginning of the COVID-19 vaccination campaign (from February 19 to June 8, 2021) in France.
N Engl J Med
April 2024
From the French Clinical Research Network (F-CRIN) for Parkinson's Disease and Movement Disorders (NS-Park-F-CRIN) (W.G.M., P.R., C. Giordana, D.M., P. Derkinderen, J.-L.H., M.A., I.B., T.B., C.B.-C., N.C., O.C., J.-C.C., P. Damier, E.D., D.D., S.D., M.F., V.F., A.F.-S., S.F.-K., S.G., C.H., L.H., P.K., B.L., R.L., L.-L.M., A.M., C.M., F.O.-M., H.S., C. Thiriez, M.T., O.R.), Centre d'Investigation Clinique (CIC) 1436 and the Departments of Clinical Pharmacology and Neurosciences, Centre Expert Parkinson, University Hospital of Toulouse, INSERM, University of Toulouse 3 (C.B.-C., H.C., M.F., F.O.-M., C. Thalamas, O.R.), and CIC 1436, INSERM (E.D., A.S.), Toulouse, Service de Neurologie des Maladies Neurodégénératives, Centre Expert Parkinson, Institut des Maladies Neurodégénératives (IMN) Clinique (W.G.M., T.B., A.F.-S., B.L.), and Service d'Information Médicale, Unité de Soutien Méthodologique à la Recherche (USMR) (A.G., C. Germain, A.B.), Centre Hospitalier Universitaire (CHU) Bordeaux, Unité Mixte de Recherche (UMR) 5293, Université de Bordeaux, Centre National de la Recherche Scientifique (CNRS), IMN, Unité Mixte de Recherche (UMR) 5293 (W.G.M., T.B., A.F.-S.), and the European Clinical Trials Platform and Development-F-CRIN, CIC-Clinical Epidemiology Unit 1401, University of Bordeaux, INSERM, Institut Bergonié, CHU Bordeaux (A.G., C. Germain, A.B.), Bordeaux, the Department of Neurology, Centre Expert Parkinson, Equipe 01-Neuropsychologie Interventionnelle L'Institut Mondor de Recherches Biomédicales, CHU Henri Mondor, INSERM et Faculté de Santé, Université Paris-Est Créteil, Créteil (P.R., H.S.), the Department of Neurology, Centre Expert Parkinson, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice (C. Giordana, V.F., C.M.), the Department of Neurology, Centre Expert Parkinson, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, UMR 1239, Rouen University Hospital, University of Rouen, INSERM, Mont-Saint-Aignan (D.M.), and the Department of Neurology, Centre Expert Parkinson, Rouen University Hospital and University of Rouen (C.H., R.L.), Rouen, the Department of Neurology, Centre Expert Parkinson, CIC 1413, CHU Nantes, INSERM, Nantes (P. Derkinderen, P. Damier), Service de Neurologie, Centre Expert Parkinson, CIC 1402, CHU Limoges, CHU Poitiers INSERM, Limoges (J.-L.H., I.B., O.C.), the Department of Neurology, Centre Expert Parkinson, Strasbourg University Hospital, and Strasbourg Federation of Translational Medicine, Strasbourg University, Strasbourg (M.A.), the Institute of Genetics and Cellular and Molecular Biology, INSERM Unité 964, CNRS-UMR 7104, University of Strasbourg, Illkirch-Graffenstaden (M.A.), the Department of Medical Pharmacology INSERM Unité 1172, Lille Neurosciences and Cognition, Centre Hospitalier Régional Universitaire, University of Lille, Lille (N.C., D.D.), the Department of Neurology, CIC Neurosciences, Sorbonne Université, Paris Brain Institute, Assistance Publique-Hôpitaux de Paris, INSERM, CNRS, Pitié-Salpêtrière Hospital, Paris (J.-C.C., L.-L.M.), the Department of Neurology, Centre Expert Parkinson, CIC 1414, CHU Pontchaillou de Rennes, INSERM, Rennes (S.D.), the Department of Neurology, Centre Expert Parkinson, CHU de Nancy, Hôpital Central, Nancy (S.F.-K., L.H.), the Department of Neurology, Centre Expert Parkinson, University Hospital La Timone, Marseille (S.G.), the Department of Neurology, Centre Expert Parkinson, University Hospital of Amiens, Amiens (P.K., M.T.), the Department of Neurology, CHU Clermont-Ferrand, Université Clermont-Auvergne, CNRS, Image Guided Clinical Neuroscience and Connectomics, Institut Pascal, Clermont-Ferrand (A.M.), the Department of Nutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac (V.R.), and the Department of Neurology, Centre Expert Parkinson, CHU de Caen, Caen (C. Thiriez) - all in France; the Department of Medicine, University of Otago, Christchurch, and the New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.); Specialized Rehabilitation Hospital, Capital Health, Abu Dhabi, United Arab Emirates (P.K.); and Cure Parkinson's, London (S.R.W.S., R.K.W.).
Background: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease.
Methods: In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period.
Antibiotics (Basel)
March 2024
CHU Lille, University of Lille, F-59000 Lille, France.
Background: In geriatrics, explicit criteria for potentially inappropriate prescriptions (PIPs) are useful for optimizing drug use.
Objective: To produce an expert consensus on explicit definitions of antibiotic-PIPs for hospitalized older patients.
Methods: We conducted a Delphi survey involving French experts on antibiotic stewardship in hospital settings.
Pediatr Allergy Immunol
March 2024
Department of Pediatric Pulmonology and Allergy, AP-HP, Hôpital Necker-Enfants Malades, Université Paris Cité, Paris, France.
Background: It is unclear whether sensitization patterns differentiate children with severe recurrent wheeze (SRW)/severe asthma (SA) from those with non-severe recurrent wheeze (NSRW)/non-severe asthma (NSA). Our objective was to determine whether sensitization patterns can discriminate between children from the French COBRAPed cohort with NSRW/NSA and those with SRW/SA.
Methods: IgE to 112 components (c-sIgE) (ImmunoCAP® ISAC) were analyzed in 125 preschools (3-6 years) and 170 school-age children (7-12 years).
Infect Dis Now
August 2024
INSERM CIC 1417 Cochin Pasteur, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Innovative Clinical Research Network in Vaccinology, Université de Paris, Sorbonne Paris Cité, Paris, France.
Bull Cancer
April 2024
Département d'hématologie et thérapie cellulaire, CHU de Saint-Étienne, 42055 Saint-Étienne cedex 2, France; Laboratoire Inserm, SAINBIOSE, U1059, dysfonction vasculaire et hémostase, université Jean-Monnet, Saint-Étienne, France; Centre d'investigation clinique CIC-EC 1408, CHU de Saint-Étienne, 42055 Saint-Étienne cedex 2, France.